Cardiome Pharma Corp. (CRME) Forms $1.45 Double Bottom; Vident Investment Advisory Has Trimmed Myriad Genetics (MYGN) Position

February 7, 2018 - By John Hoffman

Cardiome Pharma Corp. (CRME) formed double bottom with $1.39 target or 4.00% below today’s $1.45 share price. Cardiome Pharma Corp. (CRME) has $49.32 million valuation. The stock increased 2.11% or $0.03 during the last trading session, reaching $1.45. About 71,817 shares traded. Cardiome Pharma Corp. (NASDAQ:CRME) has declined 11.02% since February 7, 2017 and is downtrending. It has underperformed by 27.72% the S&P500.

Vident Investment Advisory Llc decreased Myriad Genetics Inc (MYGN) stake by 30.29% reported in 2017Q3 SEC filing. Vident Investment Advisory Llc sold 46,975 shares as Myriad Genetics Inc (MYGN)’s stock rose 13.21%. The Vident Investment Advisory Llc holds 108,092 shares with $3.91 million value, down from 155,067 last quarter. Myriad Genetics Inc now has $2.48 billion valuation. The stock increased 4.10% or $1.41 during the last trading session, reaching $35.81. About 1.01M shares traded or 28.18% up from the average. Myriad Genetics, Inc. (NASDAQ:MYGN) has declined 37.47% since February 7, 2017 and is downtrending. It has underperformed by 54.17% the S&P500.

Since September 1, 2017, it had 0 insider buys, and 8 insider sales for $6.39 million activity. On Friday, January 12 the insider MARSH RICHARD M sold $498,764. $118,934 worth of Myriad Genetics, Inc. (NASDAQ:MYGN) shares were sold by King Gary A.. On Thursday, December 14 the insider GILBERT WALTER PHD sold $248,925. $909,040 worth of Myriad Genetics, Inc. (NASDAQ:MYGN) was sold by HENDERSON JOHN T on Friday, September 1. DREISMANN HEINRICH had sold 6,000 shares worth $201,000.

Vident Investment Advisory Llc increased Gamestop Corp New (NYSE:GME) stake by 42,230 shares to 121,696 valued at $2.51M in 2017Q3. It also upped Hollyfrontier Corp (NYSE:HFC) stake by 11,684 shares and now owns 94,715 shares. Tyson Foods Inc (NYSE:TSN) was raised too.

Among 20 analysts covering Myriad Genetics (NASDAQ:MYGN), 4 have Buy rating, 5 Sell and 11 Hold. Therefore 20% are positive. Myriad Genetics had 53 analyst reports since July 21, 2015 according to SRatingsIntel. The company was initiated on Thursday, January 7 by Deutsche Bank. Jefferies maintained it with “Hold” rating and $2100 target in Monday, June 12 report. The rating was maintained by Barclays Capital on Wednesday, August 9 with “Equal-Weight”. The rating was upgraded by Deutsche Bank on Friday, August 18 to “Hold”. The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) earned “Hold” rating by Cowen & Co on Monday, August 14. Jefferies maintained Myriad Genetics, Inc. (NASDAQ:MYGN) on Friday, October 20 with “Hold” rating. The firm has “Neutral” rating by Goldman Sachs given on Tuesday, December 8. The firm has “Neutral” rating by Mizuho given on Tuesday, September 15. As per Wednesday, November 8, the company rating was maintained by Morgan Stanley. Leerink Swann maintained it with “Market Perform” rating and $41 target in Wednesday, May 4 report.

Investors sentiment decreased to 0.86 in Q3 2017. Its down 0.16, from 1.02 in 2017Q2. It dropped, as 33 investors sold MYGN shares while 72 reduced holdings. 28 funds opened positions while 62 raised stakes. 71.79 million shares or 8.95% less from 78.85 million shares in 2017Q2 were reported. Zweig reported 8,600 shares. Fisher Asset Mngmt Ltd Liability Corporation reported 120,312 shares or 0.01% of all its holdings. Employees Retirement System Of Ohio stated it has 142,609 shares or 0.03% of all its holdings. Camber Mngmt Lc accumulated 2.00 million shares. Macquarie Group owns 135,000 shares for 0.01% of their portfolio. Legal And General Group Plc reported 135,421 shares. Bb&T Securities Ltd Liability stated it has 11,338 shares. Gp Inc One Trading Lp holds 422 shares. Adams Asset Advsr Limited Liability reported 0.19% in Myriad Genetics, Inc. (NASDAQ:MYGN). Aimz Inv Advisors Llc has 0.95% invested in Myriad Genetics, Inc. (NASDAQ:MYGN). Renaissance Technology Limited reported 0.01% in Myriad Genetics, Inc. (NASDAQ:MYGN). Riverhead Mgmt Limited Company has invested 0.01% of its portfolio in Myriad Genetics, Inc. (NASDAQ:MYGN). Us State Bank De accumulated 0% or 2,287 shares. Piedmont Advsrs Limited Liability holds 68,912 shares. Qs Invsts Limited Liability Com stated it has 0% of its portfolio in Myriad Genetics, Inc. (NASDAQ:MYGN).

Analysts await Cardiome Pharma Corp. (NASDAQ:CRME) to report earnings on March, 6. They expect $-0.19 earnings per share, down 5.56% or $0.01 from last year’s $-0.18 per share. After $-0.20 actual earnings per share reported by Cardiome Pharma Corp. for the previous quarter, Wall Street now forecasts -5.00% EPS growth.

Among 6 analysts covering Cardiome Pharma Corp (NASDAQ:CRME), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cardiome Pharma Corp had 15 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was upgraded by Mackie on Friday, May 6 to “Speculative Buy”. The company was maintained on Wednesday, November 15 by Canaccord Genuity. Mackie upgraded the stock to “Buy” rating in Friday, December 15 report. The firm has “Hold” rating by Zacks given on Wednesday, August 26. The firm has “Outperform” rating by Leerink Swann given on Thursday, December 22. The stock has “Buy” rating by H.C. Wainwright on Wednesday, November 22. The firm earned “Buy” rating on Monday, July 17 by Canaccord Genuity. The firm has “Buy” rating by LB Securities given on Friday, August 14. The stock of Cardiome Pharma Corp. (NASDAQ:CRME) has “Hold” rating given on Wednesday, October 12 by Mackie. The firm earned “Buy” rating on Wednesday, June 1 by H.C. Wainwright.

Investors sentiment increased to 1.09 in 2017 Q3. Its up 0.26, from 0.83 in 2017Q2. It improved, as 2 investors sold Cardiome Pharma Corp. shares while 9 reduced holdings. 7 funds opened positions while 5 raised stakes. 13.54 million shares or 10.92% less from 15.20 million shares in 2017Q2 were reported. Clough Cap Prtnrs Lp holds 2.88M shares or 0.41% of its portfolio. 1,889 are owned by Royal Bank Of Canada. Virtu Fincl Limited Liability Corporation invested in 27,658 shares. Wells Fargo Communications Mn invested in 0% or 800 shares. Valley Natl Advisers holds 0% of its portfolio in Cardiome Pharma Corp. (NASDAQ:CRME) for 50 shares. 134,478 are owned by Knott David M. Jpmorgan Chase And holds 0% or 158,697 shares. Art Advisors Limited Liability Corp accumulated 0% or 16,718 shares. Pnc Financial Svcs Group reported 51,400 shares stake. Ardsley Advisory Prtnrs reported 0.01% in Cardiome Pharma Corp. (NASDAQ:CRME). Alphaone Investment Services Limited Company reported 0.34% of its portfolio in Cardiome Pharma Corp. (NASDAQ:CRME). Grp One Trading Ltd Partnership has 0% invested in Cardiome Pharma Corp. (NASDAQ:CRME). Morgan Stanley, a New York-based fund reported 2,100 shares. Geode Capital Management Lc holds 0% of its portfolio in Cardiome Pharma Corp. (NASDAQ:CRME) for 18,731 shares. Citadel Lc holds 0% or 16,339 shares in its portfolio.